David Allison, PhD
![](https://3tbiosciences.com/wp-content/uploads/2023/10/David-Allison-headshot.jpg)
Dr. Allison has spent the past 15 years in biotechnology venture capital and has led several IPOs and acquisitions. Before joining Westlake, he spent more than six years as a partner at 5AM Ventures where he was involved in investments including CinCor Pharma (acquired by AstraZeneca), Crinetics Pharmaceuticals, Impel Neuropharma, Inipharm, Neurogastrx, and Radionetics. Prior to 5AM, Dr. Allison was a principal at Versant Ventures and held previous roles at Split Rock Partners and PTV Healthcare Capital.